Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Relationship between Surgery and Trauma and Risk of Recurrence in Patients with an Associated First Venous Thrombotic Event: A Nested Case-Control Study.

Thrombosis and haemostasis·2025

Same author

Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19].

Thrombosis research·2020

Same author

Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.

Thrombosis research·2019

Same author

Thrombus stability explains the factor V Leiden paradox: a mouse model.

Blood advances·2019

Same author

Extended thromboprophylaxis following colorectal surgery in patients with inflammatory bowel disease: a comprehensive systematic clinical review.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2019

Same author

Overwinter Survival of Bean Rust Urediniospores in North Dakota.

Plant disease·2019

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

New antithrombotic drugs.

P L Gross¹, J I Weitz

¹Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada.

Clinical Pharmacology and Therapeutics

|June 26, 2009

Summary

This summary is machine-generated.

Researchers are developing novel antithrombotic drugs, including antiplatelet agents and anticoagulants, by targeting key biochemical pathways. The goal is to create more effective treatments with fewer bleeding risks.

Related Experiment Videos

Last Updated: Jun 22, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

Biochemistry
Pharmacology
Hematology

Background:

Thrombosis (venous and arterial) is a significant global health burden, causing widespread morbidity and mortality.
Existing antithrombotic therapies necessitate the development of novel agents with improved efficacy and safety profiles.
Understanding the intricate biochemical pathways of platelet activation, coagulation, and their interplay with inflammation is crucial for identifying new therapeutic targets.

Purpose of the Study:

To review recent advancements in the identification of novel molecular targets for antithrombotic drug development.
To discuss emerging antiplatelet agents and anticoagulants targeting these new pathways.
To highlight progress in developing antithrombotic therapies with a reduced impact on hemostasis.

Main Methods:

Literature review of recent scientific publications and clinical trial data.
Analysis of biochemical and molecular mechanisms underlying thrombosis.
Focus on novel drug targets and their corresponding therapeutic agents.

Main Results:

Identification of several new molecular targets involved in platelet aggregation and thrombus formation.
Development of novel antiplatelet drugs and anticoagulants with enhanced specificity.
Early data suggests these novel agents may offer improved antithrombotic effects with potentially reduced bleeding complications.

Conclusions:

Advances in understanding thrombosis pathophysiology have revealed promising new targets for drug development.
Novel antiplatelet and anticoagulant agents are emerging, offering potential for more effective and safer antithrombotic therapies.
Continued research is essential to optimize these new drugs for clinical application, balancing efficacy with hemostatic safety.